Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis

BACKGROUND AND OBJECTIVE: Difelikefalin, a selective kappa-opioid receptor agonist, is the first approved treatment for moderate-to-severe pruritus in patients with end-stage renal disease (ESRD) on hemodialysis (HD) in the USA and Europe. The purpose of this open-label study was to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Stark, Jeffrey G., Noonan, Patrick K., Spencer, Robert H., Bhaduri, Sarbani, O’Connor, Stephen J., Menzaghi, Frédérique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450003/
https://www.ncbi.nlm.nih.gov/pubmed/37369955
http://dx.doi.org/10.1007/s40262-023-01262-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450003/
https://www.ncbi.nlm.nih.gov/pubmed/37369955
http://dx.doi.org/10.1007/s40262-023-01262-2

Ejemplares similares